Proficio Capital Partners LLC Invests $31.94 Million in Cencora, Inc. (NYSE:COR)

Proficio Capital Partners LLC acquired a new stake in Cencora, Inc. (NYSE:COR - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 142,139 shares of the company's stock, valued at approximately $31,936,000. Proficio Capital Partners LLC owned approximately 0.07% of Cencora at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Oppenheimer & Co. Inc. boosted its stake in Cencora by 1.7% during the 4th quarter. Oppenheimer & Co. Inc. now owns 5,949 shares of the company's stock valued at $1,337,000 after purchasing an additional 99 shares during the last quarter. Mn Services Vermogensbeheer B.V. boosted its position in shares of Cencora by 1.7% during the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 66,500 shares of the company's stock valued at $14,941,000 after buying an additional 1,100 shares during the last quarter. New York Life Investment Management LLC grew its holdings in Cencora by 1.3% during the fourth quarter. New York Life Investment Management LLC now owns 23,507 shares of the company's stock worth $5,282,000 after buying an additional 303 shares in the last quarter. Whipplewood Advisors LLC purchased a new stake in Cencora in the 4th quarter valued at $137,000. Finally, Oregon Public Employees Retirement Fund lifted its stake in Cencora by 0.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 15,051 shares of the company's stock valued at $3,382,000 after acquiring an additional 120 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Performance

Shares of COR traded down $0.84 during mid-day trading on Tuesday, hitting $254.54. The stock had a trading volume of 850,177 shares, compared to its average volume of 1,483,333. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The firm has a market cap of $49.36 billion, a P/E ratio of 36.26, a PEG ratio of 1.31 and a beta of 0.49. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $262.26. The business has a fifty day moving average price of $242.26 and a 200-day moving average price of $237.98.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.86%. Cencora's payout ratio is 31.29%.

Insiders Place Their Bets

In other news, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the sale, the executive vice president now directly owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. This represents a 24.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 10.80% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Barclays upped their target price on shares of Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Mizuho began coverage on shares of Cencora in a research report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price objective for the company. JPMorgan Chase & Co. lifted their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. UBS Group upped their target price on Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a report on Thursday, November 7th. Finally, Wells Fargo & Company increased their price target on Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a research report on Wednesday, January 29th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, Cencora presently has an average rating of "Moderate Buy" and an average price target of $277.90.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.